newsfilter
← Latest News
GlobeNewswire·

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administratio